Publications by authors named "McNerney K"

This study presents an examination of the neural connectivity associated with processing speech in noisy environments, an ability that declines with age. We correlated subjects' speech-in-noise (SIN) ability with resting-state MRI scans and Fractional Anisotropy (FA) values from the auditory section of the corpus callosum, both with and without correcting for age. The results revealed that subjects who performed poorly on the right ear SIN test (QuickSIN, MedRx) had higher correlations between the primary auditory cortex and regions of the brain that process language.

View Article and Find Full Text PDF

Background: Cytokines are soluble signaling proteins that regulate inflammation and coordinate immune responses. Serum cytokine panels are increasingly used in medical practice, yet our understanding of cytokines as biomarkers for disease remains limited.

Objective: We sought to analyze real-world single-center use of a multiplexed cytokine panel, correlate its results with diagnosis and severity, and explore its use in pediatric practice.

View Article and Find Full Text PDF
Article Synopsis
  • MCT8 deficiency is a rare, X-linked disorder caused by mutations affecting thyroid hormone transport, leading to severe developmental delays and motor disabilities due to insufficient thyroid hormone in the brain.
  • Diagnosis and treatment of MCT8 deficiency face major challenges, including a lack of awareness among healthcare professionals, resulting in misdiagnoses and delays, as well as complex symptoms that may not surface until months after birth.
  • Multidisciplinary care is essential for optimal patient support, and while there are no specific treatments available yet, early diagnosis can help improve access to supportive care and developing interventions to enhance the quality of life for patients and their families.
View Article and Find Full Text PDF

Background: The goal of this study was to assess the effect of donor type and pre-transplant immunotherapy (IST) on outcomes of hematopoietic stem cell transplantation (HSCT) for children and young adults with severe aplastic anemia (SAA).

Methods: This retrospective, multi-center study included 52 SAA patients, treated in 5 pediatric transplant programs in Florida, who received HSCT between 2010 and 2020 as the first- or second-line treatment.

Results: The median age at HSCT for all 52 patients was 15 years (range 1-25).

View Article and Find Full Text PDF

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in relapsed/refractory (r/r) B cell malignancies, including in pediatric patients with acute lymphoblastic leukemia (ALL). Expanding this success to other hematologic and solid malignancies is an area of active research and, although challenges remain, novel solutions have led to significant progress over the past decade. Ongoing clinical trials for CAR T cell therapy for T cell malignancies and acute myeloid leukemia (AML) have highlighted challenges, including antigen specificity with off-tumor toxicity and persistence concerns.

View Article and Find Full Text PDF

Introduction: Cellular therapies are frequently studied in clinical trials for pediatric patients with malignant disease. Characteristics of ongoing and completed cellular therapy clinical trials in the U.S.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the use of mediports for administering CAR T cell therapy in patients with B-cell malignancies, aiming to establish standardized practices in this area due to previous concerns about effectiveness and safety.
  • Data was collected from 34 medical centers, analyzing 504 CAR T cell infusions, making it one of the largest reports on this topic since CAR T cell commercialization began in 2017.
  • Results showed that 85% of centers accepted mediports as standard practice, with no incidents of CAR T cell infiltration reported among the 184 patients infused via mediports, supporting their safe use in clinical settings.
View Article and Find Full Text PDF

Objective: Immediate type I, type III, and delayed type IV hypersensitivity reactions to insulin are rare, but potentially serious complications of exogenous insulin administration required for the treatment of type 1 diabetes (T1D).

Methods: We present four cases of insulin hypersensitivity reactions occurring in youth with T1D and a literature review of this topic.

Results: Insulin hypersensitivity reactions included types I, III, and IV with presentations ranging from localized urticaria, erythematous nodules, and eczematous plaques to anaphylaxis with respiratory distress.

View Article and Find Full Text PDF

Chimeric antigen receptor (CAR) T cell (CAR-T) therapy has emerged as a revolutionary cancer treatment modality, particularly in children and young adults with B cell malignancies. Through clinical trials and real-world experience, much has been learned about the unique toxicity profile of CAR-T therapy. The past decade brought advances in identifying risk factors for severe inflammatory toxicities, investigating preventive measures to mitigate these toxicities, and exploring novel strategies to manage refractory and newly described toxicities, infectious risks, and delayed effects, such as cytopenias.

View Article and Find Full Text PDF

Treatment with tisagenlecleucel (tisa-cel) achieves excellent complete remission rates in children and young adults with relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL), but approximately 50% maintain long-term remission. Consolidative hematopoietic stem cell transplantation (cHSCT) is a potential strategy to reduce relapse risk, but it carries substantial short- and long-term toxicities. Additionally, several strategies for management of B cell recovery (BCR) and next-generation sequencing (NGS) positivity post-tisa-cel exist, without an accepted standard.

View Article and Find Full Text PDF

Environmental factors may alter the fetal genome to cause metabolic diseases. It is unknown whether embryonic immune cell programming impacts the risk of type 2 diabetes in later life. We demonstrate that transplantation of fetal hematopoietic stem cells (HSCs) made vitamin D deficient in utero induce diabetes in vitamin D-sufficient mice.

View Article and Find Full Text PDF

Objective: Current peak serum cortisol cutoffs for the diagnosis of adrenal insufficiency (AI) after Cosyntropin stimulation have been established using polyclonal antibody (pAb) immunoassays. However, new and highly specific cortisol monoclonal antibody (mAb) immunoassays are being used more widely, which can potentially yield higher false positive rates. Thus, this study aimed to redefine the biochemical diagnostic cutoff points for AI in children when using a highly specific cortisol mAb immunoassay and liquid chromatography tandem mass spectrometry (LC/MS) to avoid unnecessary steroid use.

View Article and Find Full Text PDF

The adrenal gland cortex produces life-sustaining steroid hormones that are critical for the development and survival of the fetus and neonate. Antenatal and postnatal administration of steroids has critical therapeutic effects in preterm infants. However, prolonged postnatal steroid therapy for more than 1 to 2 weeks is associated with iatrogenic adrenal insufficiency and should prompt consideration of a steroid taper and stress dose precautions.

View Article and Find Full Text PDF
Article Synopsis
  • T cell-mediated hyperinflammatory responses, particularly cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), are recognized toxicities from CAR T cell therapy, with recent findings highlighting HLH-like toxicities as significant yet poorly defined complications.
  • A panel of experts from various medical fields has been formed to better understand and manage these HLH-like toxicities, now termed "immune effector cell-associated HLH-like syndrome (IEC-HS)," indicating a broader impact across different patient populations and CAR T cell constructs.
  • The panel proposes a framework for identifying IEC-HS, including a grading system to assess severity, and suggests treatment strategies and supportive care to improve patient outcomes and facilitate further
View Article and Find Full Text PDF

Chimeric antigen receptor-associated hemophagocytic lymphohistiocytosis (HLH)-like toxicities (LTs) involving hyperferritinemia, multiorgan dysfunction, coagulopathy, and/or hemophagocytosis are described as occurring in a subset of patients with cytokine release syndrome (CRS). Case series report poor outcomes for those with B-cell acute lymphoblastic leukemia (B-ALL) who develop HLH-LTs, although larger outcomes analyses of children and young adults (CAYAs) with B-ALL who develop these toxicities after the administration of commercially available tisagenlecleucel are not described. Using a multi-institutional database of 185 CAYAs with B-ALL, we conducted a retrospective cohort study including groups that developed HLH-LTs, high-grade (HG) CRS without HLH-LTs, or no to low-grade (NLG) CRS without HLH-LTs.

View Article and Find Full Text PDF

Background: Immunocompromised patients are at increased risk of SARS-CoV-2 infections. Patients undergoing chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell malignancies are uniquely immunosuppressed due to CAR T-mediated B-cell aplasia (BCA). While SARS-CoV-2 mortality rates of 33%-40% are reported in adult CAR T-cell recipients, outcomes in pediatric and young adult CAR T-cell recipients are limited.

View Article and Find Full Text PDF

Background: The cervical vestibular evoked myogenic potential (cVEMP) is a vestibular response that is produced by the saccule in response to intense, often low-frequency, short-duration auditory stimuli, and is typically recorded from a contracted sternocleidomastoid (SCM) muscle. Previous research has shown that the amplitude of the cVEMP is related to the amount of SCM electromyographic (EMG) activity.

Purpose: The aim of this study was to determine the influence of various remote motoric maneuvers on the amplitude of the cVEMP, as well as whether they influence the level of SCM EMG activity.

View Article and Find Full Text PDF

Neuroblastoma is a commonly lethal solid tumor of childhood and intensive chemoradiotherapy treatment cures ~50% of children with high-risk disease. The addition of immunotherapy using dinutuximab, a monoclonal antibody directed against the GD2 disialoganglioside expressed on neuroblasts, improves survival when incorporated into front-line therapy and shows robust activity in regressing relapsed disease when combined with chemotherapy. Still, many children succumb to neuroblastoma progression despite receiving dinutuximab-based immunotherapy, and efforts to counteract the immune suppressive signals responsible are warranted.

View Article and Find Full Text PDF

Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-tumor antibiotic conjugate with proven efficacy in pediatric and adult patients with CD33+ acute myeloid leukemia. Adverse effects commonly associated with GO include hyperbilirubinemia, elevated transaminases, and sinusoidal obstruction syndrome. Cardiotoxicity has not been a commonly described adverse event.

View Article and Find Full Text PDF

Here we review the pathophysiology and management of cytokine release syndrome (CRS) secondary to immunotherapy, and potential options for CRS refractory to IL6 inhibition and glucocorticoids, for which there are no proven treatments. To illustrate, we describe a patient with B-cell acute lymphoblastic leukemia who developed refractory grade 4 CRS following CD19-directed chimeric antigen receptor T-cell therapy, treated with tocilizumab, methylprednisolone, siltuximab, and the IFNγ inhibitor emapalumab, with complete remission from leukemia for 12 months. See related article by Bailey et al.

View Article and Find Full Text PDF
Article Synopsis
  • - Multi-system Inflammatory Syndrome in Children (MIS-C) is a serious condition that can arise in kids after having a mild or asymptomatic COVID-19 infection, leading to severe inflammation and shock-like symptoms.
  • - Researchers analyzed over 1,400 proteins in the plasma of children with COVID-19 to understand the causes of hyperinflammation and vascular damage, finding common protein signatures with other inflammatory conditions.
  • - They identified PLA2G2A as a key marker associated with MIS-C and discovered that the immune response related to IFNγ is altered in these patients, which helps to explain the variation in clinical symptoms.
View Article and Find Full Text PDF

Objectives: The diagnosis of adrenal insufficiency relies on clear cut-offs and accurate measurement of cortisol levels. Newer monoclonal antibody assays may increase the rate of diagnosis of adrenal insufficiency if traditional cortisol cut-off levels <18 mcg/dL (500 nmol/L) are applied. We aimed to determine if the rate of diagnosis of adrenal insufficiency using a 1 mcg Cosyntropin stimulation test varied with the change in cortisol assay from a polyclonal to a monoclonal antibody assay.

View Article and Find Full Text PDF

Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in pediatric patients. Weeks after an often mild or asymptomatic initial infection with SARS-CoV-2 children may present with a severe shock-like picture and marked inflammation. Children with MIS-C present with varying degrees of cardiovascular and hyperinflammatory symptoms.

View Article and Find Full Text PDF